Mary Romero
Family · Naples, FLNPI 1407592264
Payments from drug & device makers
Across 129 payments — averaging $29.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Phathom Pharmaceuticals, Inc.$639
- AbbVie$562
- Takeda Pharmaceuticals U.S.A., Inc.$342
- Madrigal Pharmaceuticals$295
- Regeneron Healthcare Solutions, Inc.$221
- Exact Sciences$188
- plus $2K from 38 others
What the payments were for
- Food & beverage$3,849100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VOQUEZNA$471
- REZDIFFRA$257
- ZEPOSIA$121
- Cologuard Collection Kit$117
How this compares
$3,849 in reported general payments places this provider in the 90th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 13 | $32,169 |
| XifaxanRifaximin | 14 | $28,411 |
| LinzessLinaclotide | 13 | $13,196 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 115 | $7,137 |
| Rabeprazole Sodium | 42 | $3,625 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 22 | $3,549 |
| Pantoprazole Sodium | 142 | $1,785 |
| Sucralfate | 22 | $1,340 |
| Ursodiol | 21 | $1,099 |
| CholestyramineCholestyramine (With Sugar) | 16 | $799 |
| Colestipol Hcl | 14 | $794 |
| Dicyclomine Hcl | 31 | $674 |
| Neomycin Sulfate | 12 | $470 |
| Omeprazole | 39 | $446 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 20 | $266 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $562 | $45,36526 claims |
| Braintree Laboratories, Inc.Sutab | $88 | $3,54922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 14,618 family providers in Florida.
Other family in Naples
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.